ViroCyt, a developer of rapid quantification technology for viruses, has added new investors to its most recent round of funding. This financing brings the round total to $5 million and was an extension of the initial close, which occurred in November 2012. ViroCyt backers include High Country Venture and several angel networks.The Denver-based company offers a product called Virus Counter 2100, which provides rapid quantification of intact viral particles—an approach designed to minimize the costs and delays associated with more traditional methods.
